Plaque psoriasis is the most common type of ... but treatment can help manage your symptoms. If you have mild psoriasis, a doctor may recommend home remedies and over-the-counter treatments.

Less than a quarter of patients diagnosed with mild psoriasis had a body surface area of less than 3% at the time of diagnosis.

SFA Therapeutics, Inc. has announced encouraging results from its Phase 1b clinical trial of SFA-002, an oral drug candidate aimed at treating mild-to-moderate psoriasis. The study demonstrated both ...

The AAD/NPF guidelines define mild psoriasis as <3% BSA and ... I use roflumilast for inverse psoriasis and tapinarof for thicker plaque psoriasis." Cheng said insurance considerations often ...

Otezla may cause mild side effects other than the ones ... Otezla is approved for the treatment of moderate to severe plaque psoriasis in children ages 6 years and older. The drug is prescribed ...

"Mild-to-moderate patients represent over 80% of all plaque psoriasis cases, and for these patients, current effective oral treatment options are limited. Our belief is that SFA-002 is uniquely ...

The latest FDA approval was based on the results of the ADVANCE trial, which showed that five times as many adults with mild to moderate plaque psoriasis receiving oral Otezla 30 mg twice daily ...

Several classification systems, all based on disease severity, have been created to guide treatment decisions in psoriasis. In the most widely used system, disease severity is scored according to ...

Late-breaking Oral Presentation Efficacy and Safety of a Highly Selective Oral TYK2 Inhibitor, ICP-488, in Patients with Moderate-to-Severe Plaque ... and were mild or moderate. Psoriasis is ...

LEO Pharma and Reig Jofre have entered into a partnership aimed at improving access to LEO’s psoriasis treatment in Europe.